{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:48:33Z","timestamp":1794012513554,"version":"4.8.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100767"],"award-info":[{"award-number":["82100767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20191075"],"award-info":[{"award-number":["BK20191075"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Hospital","award":["JSPH-MC-2021-14"],"award-info":[{"award-number":["JSPH-MC-2021-14"]}],"id":[{"id":"https:\/\/ror.org\/04py1g812","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Project of Bethune PuAi Medical Research Fund","award":["PAYJ-058"],"award-info":[{"award-number":["PAYJ-058"]}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Medical Key Discipline (Laboratory) Cultivation Unit","award":["JSDW202206"],"award-info":[{"award-number":["JSDW202206"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Membranous nephropathy (MN) is a frequent cause of nephrotic syndrome in adults with variable response to rituximab (RTX) therapy. While traditional markers like proteinuria and anti-phospholipase A2 receptor (PLA2R) antibodies exhibit predictive value, their limitations necessitate more robust biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively analysed 149 MN patients receiving RTX over 12\u00a0months. Inflammatory indices such as neutrophil:lymphocyte ratio (NLR), monocyte:lymphocyte ratio (MLR) and systemic inflammation response index (SIRI) together with B cell levels were measured alongside conventional markers at baseline, 3\u00a0months and 6\u00a0months. Predictive models for 6- and 12-month remission (complete\/partial) were developed using multivariate regression and receiver operating characteristics (ROC) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Non-responders exhibited persistently elevated inflammatory markers (NLR, MLR, SIRI) throughout the entire observation period. Among the three, only SIRI can independently predict the remission of MN. At 3\u00a0months, SIRI \u22641.25 {odds ratio [OR] 3.68 [95% confidence interval (CI) 1.39\u20139.72]} and B cell proportion \u22640.2% [OR 2.90 (95% CI 1.00\u20138.35)] independently predicted 6-month response. Incorporating these two newly added indicators into the traditional variable model, which includes the levels of proteinuria, albumin and anti-PLA2R antibody at 3\u00a0months, markedly enhances prediction accuracy [area under the curve (AUC) 0.86 versus 0.81]. By 6\u00a0months, only SIRI \u22640.9 [OR 4.84 (95% CI 1.43\u201316.40)] and albumin change [OR 1.11 (95% CI 1.03\u20131.19)] predicted 12-month prognosis, as B cell and anti-PLA2R antibody levels lost significance. The prediction model incorporating SIRI also had better performance (AUC 0.82 versus 0.79).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>B lymphocyte levels constitute a robust predictive biomarker for assessing short-term therapeutic response in patients with MN receiving RTX therapy. Furthermore, SIRI emerges as a valuable prognostic indicator capable of predicting both short-term efficacy and long-term renal outcomes. These findings suggest that concurrent monitoring of B lymphocyte levels and SIRI values warrants integration into standardized monitoring frameworks within clinical management protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf396","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:00:41Z","timestamp":1766062841000},"source":"Crossref","is-referenced-by-count":3,"title":["Systemic inflammation and B cell indices predict rituximab responses in membranous nephropathy"],"prefix":"10.1093","volume":"19","author":[{"given":"Suyan","family":"Duan","sequence":"first","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyou","family":"Ye","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hujia","family":"Hua","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zeng","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengning","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanggang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changying","family":"Xing","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Mao","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing Medical University Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University, , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026022623062517500_bib1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026022623062517500_bib2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026022623062517500_bib3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/j.akdh.2024.04.004","article-title":"Membranous nephropathy: updates on management","volume":"31","author":"Bharati","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"2026022623062517500_bib4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.5114\/aoms.2020.99899","article-title":"Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis","volume":"19","author":"Zhong","year":"2023","journal-title":"Arch Med Sci"},{"key":"2026022623062517500_bib5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026022623062517500_bib6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"2026022623062517500_bib7","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026022623062517500_bib8","doi-asserted-by":"publisher","first-page":"106504","DOI":"10.1016\/j.intimp.2020.106504","article-title":"The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients","volume":"84","author":"Yang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2026022623062517500_bib9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaad.2023.12.064","article-title":"Baseline serum neutrophil-to-lymphocyte ratio in acral melanoma compared with nonacral melanoma and its prognostic significance","volume":"90","author":"Choi","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026022623062517500_bib10","doi-asserted-by":"crossref","first-page":"1115031","DOI":"10.3389\/fimmu.2023.1115031","article-title":"The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib11","doi-asserted-by":"publisher","first-page":"2337729","DOI":"10.1080\/07853890.2024.2337729","article-title":"Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann Med"},{"key":"2026022623062517500_bib12","doi-asserted-by":"publisher","first-page":"1526095","DOI":"10.3389\/fimmu.2025.1526095","article-title":"Aberrations in peripheral B lymphocytes and B lymphocyte subsets levels in Parkinson disease: a systematic review","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib13","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.2147\/IJGM.S384706","article-title":"The clinical value of systemic inflammatory response index and inflammatory prognosis index in predicting 3-month outcome in acute ischemic stroke patients with intravenous thrombolysis","volume":"15","author":"Ma","year":"2022","journal-title":"Int J Gen Med"},{"key":"2026022623062517500_bib14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/JIR.S451190","article-title":"The associations of two novel inflammation biomarkers, SIRI and SII, with mortality risk in patients with chronic heart failure","volume":"17","author":"Zhu","year":"2024","journal-title":"J Inflamm Res"},{"key":"2026022623062517500_bib15","doi-asserted-by":"publisher","first-page":"863640","DOI":"10.3389\/fimmu.2022.863640","article-title":"Systemic immune-inflammation index is associated with increased urinary albumin excretion: a population-based study","volume":"13","author":"Qin","year":"2022","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/IJNRD.S489455","article-title":"Different dosage regimens of rituximab in primary membranous nephropathy treatment: a systematic review","volume":"17","author":"Yu","year":"2024","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2026022623062517500_bib17","doi-asserted-by":"publisher","first-page":"109211","DOI":"10.1016\/j.clim.2022.109211","article-title":"Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury: a two-center prospective cohort study","volume":"246","author":"Xu","year":"2023","journal-title":"Clin Immunol"},{"key":"2026022623062517500_bib18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12882-023-03206-1","article-title":"Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Nephrol"},{"key":"2026022623062517500_bib19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2026022623062517500_bib20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026022623062517500_bib21","first-page":"5","article-title":"Ratio of neutrophil to lymphocyte counts\u2014rapid and simple parameter of systemic inflammation and stress in critically ill","volume":"102","author":"Zahorec","year":"2001","journal-title":"Bratisl Lek Listy"},{"key":"2026022623062517500_bib22","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2026022623062517500_bib23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ajem.2019.10.023","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: a meta-analysis","volume":"38","author":"Huang","year":"2020","journal-title":"Am J Emerg Med"},{"key":"2026022623062517500_bib24","doi-asserted-by":"publisher","first-page":"1372731","DOI":"10.3389\/fcell.2024.1372731","article-title":"Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study","volume":"12","author":"Wang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"2026022623062517500_bib25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12967-022-03425-4","article-title":"Association of monocyte-lymphocyte ratio and proliferative diabetic retinopathy in the U.S. population with type 2 diabetes","volume":"20","author":"Wang","year":"2022","journal-title":"J Transl Med"},{"key":"2026022623062517500_bib26","doi-asserted-by":"publisher","first-page":"1613483","DOI":"10.3389\/fimmu.2025.1613483","article-title":"Relationship between lymphocyte-related parameters and the prognosis of patients with lupus nephritis","volume":"16","author":"Qi","year":"2025","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10555-025-10246-6","article-title":"Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis","volume":"44","author":"Ezdoglian","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"2026022623062517500_bib28","doi-asserted-by":"publisher","first-page":"1338025","DOI":"10.3389\/fimmu.2024.1338025","article-title":"Systemic Inflammatory Response Index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease: evidence from NHANES (2001\u20132018)","volume":"15","author":"Gu","year":"2024","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib29","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/cncr.30057","article-title":"A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy","volume":"122","author":"Qi","year":"2016","journal-title":"Cancer"},{"key":"2026022623062517500_bib30","doi-asserted-by":"publisher","first-page":"11177","DOI":"10.2147\/JIR.S529125","article-title":"Systemic immune-inflammatory index and systemic inflammatory response index in the assessment of multiple organ dysfunction syndrome caused by wasp stings","volume":"18","author":"Zhang","year":"2025","journal-title":"J Inflamm Res"},{"key":"2026022623062517500_bib31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12933-025-02692-x","article-title":"Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in cardiovascular-kidney-metabolic syndrome stage 0\u20133: a nationwide prospective cohort study","volume":"24","author":"Chen","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026022623062517500_bib32","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1080\/07853890.2022.2104919","article-title":"Systemic inflammatory response index over neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio: comparison of prognostic performance in predicting major adverse cardiac events","volume":"54","author":"Mangalesh","year":"2022","journal-title":"Ann Med"},{"key":"2026022623062517500_bib33","doi-asserted-by":"publisher","first-page":"e103381","DOI":"10.1136\/bmjopen-2025-103381","article-title":"Association between complete blood count-derived inflammatory biomarkers and renal failure: a cross-sectional study from NHANES 2007\u20132020","volume":"15","author":"Li","year":"2025","journal-title":"BMJ Open"},{"key":"2026022623062517500_bib34","doi-asserted-by":"publisher","first-page":"1323174","DOI":"10.3389\/fimmu.2024.1323174","article-title":"Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: evidence from NHANES","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib35","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","article-title":"Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy","volume":"18","author":"Barbour","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026022623062517500_bib36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"2026022623062517500_bib37","first-page":"2545","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume-title":"J Am Soc Nephrol","author":"Ruggenenti","year":"2015"},{"key":"2026022623062517500_bib38","doi-asserted-by":"publisher","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib39","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026022623062517500_bib41","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/iid3.499","article-title":"Long-term B cell depletion associates with regeneration of kidney function","volume":"9","author":"Fleig","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"2026022623062517500_bib42","doi-asserted-by":"publisher","first-page":"1651810","DOI":"10.3389\/fimmu.2025.1651810","article-title":"Spontaneous remission in primary membranous nephropathy: mechanisms, predictive factors, and implications for personalized management","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"2026022623062517500_bib43","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1053\/j.ajkd.2015.07.006","article-title":"AJKD atlas of renal pathology: membranous nephropathy","volume":"66","author":"Fogo","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026022623062517500_bib44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s11255-023-03803-x","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio on proteinuria remission in patients with idiopathic membranous nephropathy","volume":"56","author":"Gan","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"2026022623062517500_bib45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","article-title":"The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey","volume":"56","author":"Glassock","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2026022623062517500_bib46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev-pathol-020117-043811","article-title":"Molecular pathogenesis of membranous nephropathy","volume":"15","author":"Ronco","year":"2020","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2026022623062517500_bib47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf396\/66002194\/sfaf396.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/2\/sfaf396\/66002194\/sfaf396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/2\/sfaf396\/66002194\/sfaf396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:06:35Z","timestamp":1772165195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf396\/8383409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf396","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,18]]},"article-number":"sfaf396"}}